New partnership between Omnicell & South East London NHS Integrated Care System will improve patient safety and drive efficiency across the region
Half a million women a year die of breast cancer and yet if detected early enough it’s one of the most survivable cancers. Micrima believe the key is early detection.
This requires a method of imaging that is radiation free and comfortable for women so screening can be carried out frequently, from a young age, that women are willing to attend. Micrima have developed the CE marked MARIA® system which uses radio-waves and involves no breast compression.
Today it’s being used in symptomatic clinics as an adjunct to other imaging modalities to reduce the chances of missing a cancer.
In clinical trials it has proven effective at cancer detection particularly in dense tissue, which also occurs most frequently, but not exclusively in younger women.
Further development of MARIA® is ongoing using the clinical data we have, as a result of multiple trials, with machine learning we are further improving our detection and giving an indicator of likelihood of a finding being cancer, (A classifier). This is a significant step forward in breast imaging.
To find out more about this technology contact us on info@micrima.com or check out Micrima.com for the latest information and to sign up to receive our newsletter.
New partnership between Omnicell & South East London NHS Integrated Care System will improve patient safety and drive efficiency across the region
BiGDUG saves customers time, space and money by offering the best storage solutions, to bring ord
In this article, Tom Russell, Programme Manager for Health and Social Care at techUK, explains why 2020 was the year of digital health... or was it?
Christian Norris and Stephen Farrington explain how Covid-19 has changed hospital infrastructure needs for good